Parathyroid hormone gene variation contributes to femoral neck geometry

Bone ◽  
2009 ◽  
Vol 44 ◽  
pp. S342
Author(s):  
F. McGuigan⁎ ◽  
M. Tenne ◽  
H. Luthman ◽  
H. Ahlborg ◽  
K. Obrant ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Femoral Neck ◽  
Gene Variation ◽  
Femoral Neck Geometry

Age-related changes in female femoral neck geometry: Implications for bone strength

1993 ◽  
Vol 53 (S1) ◽  
pp. S41-S46 ◽  
Author(s):  
Thomas J. Beck ◽  
Christopher B. Ruff ◽  
Khem Bissessur
Keyword(s):  
Femoral Neck ◽  
Bone Strength ◽  
Age Related ◽  
Femoral Neck Geometry ◽  
Age Related Changes

scholarly journals Bone Mineral Density, Parathyroid Hormone, and Vitamin D After Gastric Bypass Surgery: a 10-Year Longitudinal Follow-Up

2020 ◽  
Vol 30 (12) ◽  
pp. 4995-5000
Author(s):  
Mustafa Raoof ◽  
Ingmar Näslund ◽  
Eva Rask ◽  
Eva Szabo
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Gastric Bypass ◽  
Parathyroid Hormone ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Gastric Bypass Surgery ◽  
Serum Levels ◽  
Massive Weight Loss ◽  
Mineral Density

Abstract Background The aim of the present study was to study longitudinal changes in bone mineral density (BMD), vitamin D, and parathyroid hormone (PTH) levels in females over a 10-year period after laparoscopic Roux-en-Y gastric bypass (LRYGB). Methods Twenty-three women, mean age 43.4 ± 8.7 years and mean body mass index (BMI) 44.6 ± 5.17 kg/m2 at baseline, were included. BMD, BMI, S-calcium, S-25(OH)-vitamin D, and fP-PTH were measured preoperatively and 2, 5, and 10 years postoperatively. Results Ten years after surgery, BMD of the spine and femoral neck decreased by 20% and 25%, respectively. Changes in serum levels of vitamin D, PTH, and calcium over the same period were small. Conclusion After LRYGB with subsequent massive weight loss, a large decrease in BMD of the spine and femoral neck was seen over a 10-year postoperative period. The fall in BMD largely occurred over the first 5 years after surgery.

scholarly journals Variation in the PTH Gene, Hip Fracture, and Femoral Neck Geometry in Elderly Women

2010 ◽  
Vol 86 (5) ◽  
pp. 359-366 ◽  
Author(s):  
M. Tenne ◽  
F. E. McGuigan ◽  
H. Ahlborg ◽  
P. Gerdhem ◽  
K. Åkesson
Keyword(s):  
Hip Fracture ◽  
Femoral Neck ◽  
Elderly Women ◽  
Femoral Neck Geometry

scholarly journals Functional and association analysis of frizzled 1 (FZD1) promoter haplotypes with femoral neck geometry

Bone ◽  
2010 ◽  
Vol 46 (4) ◽  
pp. 1131-1137 ◽  
Author(s):  
Yingze Zhang ◽  
Allison L. Kuipers ◽  
Laura M. Yerges-Armstrong ◽  
Cara S. Nestlerode ◽  
Zhao Jin ◽  
...  
Keyword(s):  
Femoral Neck ◽  
Association Analysis ◽  
Femoral Neck Geometry ◽  
Promoter Haplotypes

Femoral neck geometry in overweight and normal weight adolescent girls

2010 ◽  
Vol 28 (5) ◽  
pp. 595-600 ◽  
Author(s):  
Rawad El Hage ◽  
Elie Moussa ◽  
Christophe Jacob
Keyword(s):  
Femoral Neck ◽  
Adolescent Girls ◽  
Normal Weight ◽  
Femoral Neck Geometry

scholarly journals SAT-LB64 Teriparatide and Its Bone Healing Power

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Aneeta J Joseph ◽  
Jesus L Penabad ◽  
Antonio Pinero-Pilona
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Parathyroid Hormone ◽  
Lumbar Spine ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Mineral Density ◽  
Amino Terminal ◽  
Traumatic Fracture ◽  
C2 Fracture

Abstract Introduction: Teriparatide, a parathyroid hormone analog, is an important anabolic agent approved by the U.S. Food and Drug Administration to increase bone mineral density in osteoporotic patients. Parathyroid hormone (PTH) regulates calcium, phosphate, and active vitamin-D metabolites.The amino terminal peptide fragments of PTH has been known to increase bone mass and are being used in clinical practice for osteoporosis management (1). Current literature shows the efficacy of teriparatide in increasing bone density of lumbar spine and femoral neck, and decreasing the risk of vertebral and non-vertebral fractures both in postmenopausal women and men. It is also known to prevent fractures in patients with osteoporosis and promote healing of fractures (2). Case Description: A 79-year-old Hispanic female with history of osteopenia and major lumbar spine wedge compression fractures presented to our clinic for consultation. She was on ibandronate for the past four months and was having symptoms of pill esophagitis. Her last bone mineral density done on August 2017 revealed T-score of -2.5 at the lumbar spine, -1.5 at the left femoral neck, and 3.3% bone loss on the left femoral head. Rather than being started on teriparatide, zoledronic acid, or denosumab, she continued ibandronate along with calcium and vitamin D. Two months after the initial consultation, she sustained a traumatic fracture of the posterior arch and body of C2 bilaterally following a motor vehicle accident. There were discussions about starting anabolic treatment, as serial imaging did not show any significant improvement in the healing process despite the use of a collar. Two months after sustaining C2 fracture, she was started on teriparatide. Repeat cervical spine x-ray three months later showed complete healing of the C2 fracture. Discussion: There are a limited number of cases reported in regards to teriparatide induced healing of non-osteoporotic fractures (3). Our case is one of the very few reported to have shown complete radiographic and clinical healing of a traumatic, non-osteoporotic fracture after use of teriparatide for 12 weeks.

scholarly journals Effects of anti-osteoporosis therapy on plasma aldosterone and renin

2020 ◽  
Vol 21 (2) ◽  
pp. 147032032092887
Author(s):  
Qingfen Hu ◽  
Kangla Liao ◽  
Longwei Zhang ◽  
Xiaoyu Shu ◽  
Zhixin Xu ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Femoral Neck ◽  
Postmenopausal Osteoporosis ◽  
Plasma Renin ◽  
Osteoporosis Treatment ◽  
Plasma Aldosterone ◽  
Mineral Density ◽  
Osteoporosis Therapy ◽  
Plasma Aldosterone Concentration ◽  
T Score

Objective: This study aimed to investigate the effect of anti-osteoporosis therapy on plasma aldosterone concentration (PAC), plasma renin concentration (PRC) and the aldosterone/renin ratio (ARR) in patients with postmenopausal osteoporosis. Methods: In 60 patients with postmenopausal osteoporosis, bone mineral density (BMD), PAC and PRC were measured before and after treatment with alendronate (70 mg/week, n=22) or recombinant human parathyroid hormone (20 μg/day, n=35) for 48 weeks. Results: PAC was negatively correlated with the T-score of lumbar spine BMD and femoral neck BMD (lumbar r=−0.386, p<0.01; femoral neck r=−0.262, p<0.05). With the improvement in lumbar BMD after anti-osteoporosis treatment (T-score −3.4±0.5 vs. –3.1 ±0.4, p<0.0001), PAC decreased from 182.8±53.2 to 143.7±68.6 pg/mL ( p<0.0001), PRC increased from 7.8±11.6 to 39.2±50.0 μIU/mL ( p<0.0001) and the ARR decreased from 74.8±75.2 to 13.1±17.1 pg/μIU ( p<0.0001). At baseline, 58% (35/60) of the patients had an ARR >37 pg/μIU, and the proportion decreased to 8% (5/57) after treatment. Conclusion: Treatment with alendronate or parathyroid hormone causes decreased PAC and increased PRC, resulting in a decreased ARR in postmenopausal women with osteoporosis.

Sign in / Sign up

Export Citation Format

Share Document